TABLE 1.
Baseline characteristics of 253 premenopausal HR+/HER2+ patients.
| Characteristics | Cases | Percentage |
|---|---|---|
| Age/year | ||
| ≤40 | 103 | 40.7% |
| >40 | 150 | 59.3% |
| Histological grade | ||
| I–II | 133 | 52.6% |
| III | 120 | 47.4% |
| Tumor size/cm | ||
| ≤2 | 118 | 46.6% |
| >2 | 135 | 53.4% |
| Lymph node status | ||
| Negative | 116 | 45.8% |
| Positive | 137 | 54.2% |
| Ki67 index | ||
| <30% | 59 | 23.3% |
| ≥30% | 194 | 76.7% |
| ER status | ||
| <50% | 52 | 20.6% |
| ≥50% | 201 | 79.4% |
| PR status | ||
| <50% | 99 | 39.1% |
| ≥50% | 154 | 60.9% |
| LVI | ||
| Negative | 145 | 57.3% |
| Positive | 86 | 34.0% |
| Unknown | 22 | 8.7% |
| Surgery | ||
| Lumpectomy | 60 | 23.7% |
| Mastectomy | 193 | 76.3% |
| Chemotherapy regimen | ||
| Nonanthracycline | 68 | 26.9% |
| Anthracycline‐based | 183 | 72.3% |
| Unknown | 2 | 0.8% |
| Endocrine therapy | ||
| TAM/TOR‐only | 141 | 55.7% |
| TAM/TOR/AI+OFS | 112 | 44.3% |
| Radiation therapy | ||
| No | 83 | 32.8% |
| Yes | 158 | 62.5% |
| Unkonwn | 12 | 4.7% |
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LVI, lymphovascular invasion; OFS, ovarian function suppression; PR, progesterone receptor; TAM, tamoxifen; TOR, toremifene.